In today’s briefing:
- IPO Databook: Zhejiang Energy Marine Environmental Technology (HK) – Aug 2026
- IPO Databook: Suzhou Genhouse Bio (HK) – Aug 2026
- IPO Databook: My Size (MYSZ US) – Aug 2026
- Milky Mist Dairy IPO: Not Misty For Sure, Investors Can Expect A Milky Way To Growth
- Aequitas ECM Weekly (10 August 2026)- HK Trip Notes, Innolight, Shein, Manipal, Leap, LIC, Bizlink
- IPO Databook: Splash Beverage Group (SBEV US) – Aug 2026
- IPO Databook: Veradermics (MANE US) – Aug 2026
- Pre-IPO SmartMore – Valuation Premium Is Expected
- IPO Databook: Change Agents (CHGA US) – Aug 2026
- IPO Databook: DataMeds AI (MEDS US) – Aug 2026
IPO Databook: Zhejiang Energy Marine Environmental Technology (HK) – Aug 2026
- Zhejiang Energy Marine Environmental Technology Co., Ltd, founded in 2018, is a leading global green shipping equipment and systems provider. It offers five business lines and was the largest provider.
- The company was the largest global green shipping equipment and system provider by revenue in 2025. Revenue increased by 89.4% from RMB1.32 billion (5M2025) to RMB2.51 billion (5M2026).
- Revenue was RMB2,507,000 thousand (5M2026) and profit for the period was RMB622,104 thousand (5M2026). Total assets were RMB4,119,286 thousand as of May 31, 2026.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.
IPO Databook: Suzhou Genhouse Bio (HK) – Aug 2026
- Suzhou Genhouse Bio Co., Ltd., founded in May 2014, develops innovative oncology drug candidates, focusing on RAS signaling pathways and synthetic lethality mechanisms. It seeks a primary HKEX Main Board.
- Suzhou Genhouse Bio owns 38 granted patents and 120 patent applications, with GH21 being the second clinically advanced SHP2 inhibitor globally.
- Revenue was RMB557,741 for five months ended May 31, 2026, while 2024 saw a RMB(151,775) loss.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.
IPO Databook: My Size (MYSZ US) – Aug 2026
- My Size, Inc. is a fashion technology company with an integrated portfolio addressing size, fit, inventory, circular economy, and international distribution. Its strategy is to build an integrated fashion platform.
- My Size operates Naiz Fit, Orgad, and Percentil. It entered an Equity Purchase Agreement with Square Gate Capital for up to $10.0 million in common stock purchases.
- The Company incurred significant losses and negative cash flows, raising substantial doubt about its ability to continue as a going concern. Its MVLS was $2.1 million.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.
Milky Mist Dairy IPO: Not Misty For Sure, Investors Can Expect A Milky Way To Growth
- Milky Mist Dairy launched India IPO to raise nearly INR 15.53B. The company is a packaged food company exclusively focused on value-added products within the dairy market.
- Company intends to use the proceeds for repayment/ prepayment of certain outstanding borrowings, for expansion and modernisation of Perundurai manufacturing facility and for working capital purpose.
- Milky Mist’s assertive aggressive growth initiatives alongside the market prospects make the valuation multiple it is seeking, seem reasonable.
Aequitas ECM Weekly (10 August 2026)- HK Trip Notes, Innolight, Shein, Manipal, Leap, LIC, Bizlink
- Aequitas Research’s weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.
- On the IPO front, SBI Funds Management didn’t deliver a blockbuster listing but managed to get the India ECM pipeline moving along.
- Goverment of India too jumped on the ECM revivial in India to offload a large chunk of Life Insurance of India (LICI IN).
IPO Databook: Splash Beverage Group (SBEV US) – Aug 2026
- Splash Beverage Group, Inc. is transitioning from a beverage brand company to regulated cannabinoid and wellness markets. It acquired exclusive worldwide rights to CannEpil®, a pharmaceutical product for epilepsy and.
- The company is transitioning to regulated cannabinoid and wellness markets, acquiring exclusive worldwide rights to CannEpil® on July 6, 2026. A one-for-four reverse stock split was effected July 24, 2026.
- The company reported a net loss from continuing operations of $(2,136,469) for the three months ended March 31, 2026. Auditors noted going concern issues.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.
IPO Databook: Veradermics (MANE US) – Aug 2026
- Veradermics is a dermatologist-founded, late clinical-stage biopharmaceutical company developing innovative therapeutics for aesthetic and dermatological conditions, initially focusing on VDPHL01 for pattern hair loss.
- Veradermics is developing VDPHL01, an oral, non-hormonal extended-release minoxidil formulation for pattern hair loss affecting 80 million US individuals.
- Future sales of registered securities and equity/debt issuances may cause common stock price decline and substantial dilution to existing stockholders.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.
Pre-IPO SmartMore – Valuation Premium Is Expected
- The value of SmartMore’s business model is based on IndustryGPT, combined with sensors and robots, it achieves a leap from “single-point AI” to “system-level AI”, effectively solving industry pain points.
- The “software and hardware integration” approach leads to a “heavy” business model, with higher demands for supply chain, hardware manufacturing, after-sales maintenance, and may result in lower asset turnover rates.
- As an industry leader with faster growth, SmartMore can enjoy a certain premium. If based on 2026 forecast, market value could be about RMB9.1 billion – RMB12.2 billion.
IPO Databook: Change Agents (CHGA US) – Aug 2026
- Change Agents Corporation is a technology-focused company developing innovative Agentic AI software and consumer health products, expanding into drone interception and surveillance AI enhanced technology solutions.
- The company is developing innovative Agentic AI software, consumer health products, Catch-Up video platform, Beacon GEO search product, and distributes the FDA-registered Keto Air device.
- The company had an accumulated deficit of approximately $110.4 million as of March 31, 2026, and $200,000 cash as of July 31, 2026, raising going concern doubt.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.
IPO Databook: DataMeds AI (MEDS US) – Aug 2026
- DataMeds AI, Inc. is a holding company for operating companies focused on healthcare technology and pharmaceutical services, aiming to be a micro health ecosystem.
- DataMeds AI is a 50-state FDA licensed pharmaceutical wholesaler distributor, serving over 5,000 registered pharmacies nationwide with a network of over 19,000.
- The company has a history of losses and anticipates continuing losses, receiving a Nasdaq non-compliance notice for minimum stockholders’ equity.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

